The Role of Immunotherapy in the Treatment of Metastatic Gastric Cancer (IASGO 2026) - Sep 23, 2026 - Abstract #SY30-4; Pres time: Sep 11, 2026; 09:00 AM - 10:30 AM; "HERIZON-GEA-01 showed thatzanidatamab plus chemotherapy improved progression-free survival versus trastuzumab pluschemotherapy, while adding tislelizumab also produced an encouraging overall-survival benefit...Nivolumab plus ipilimumab failed to improve survival in CheckMate 649, andATTRACTION-6 increased response rate without improving overall survival and caused greater toxicity.However, in MSI-H/dMMR advanced G/GEJC, the phase II NO LIMIT trial showed robust and durableactivity with first-line nivolumab plus low-dose ipilimumab, supporting biomarker-defined dualcheckpoint blockade...The EP4 antagonist ONO-4578 plus nivolumab and chemotherapy showed encouragingphase II activity. ASP2138, a CLDN18.2/CD3 bispecific T-cell engager, is being evaluated withpembrolizumab and chemotherapy, while zolbetuximab plus nivolumab and chemotherapy showedpromising activity in ILUSTRO and is being tested in phase III LUCERNA. Future progress will depend on biomarker-driven..."
IO biomarker • Metastases • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • HER-2 • MSI • PD-L1 • TIGIT
|